Pharmabio Serv, Inc. (PBSV) SEC Filing 8-K Material Event for the period ending Friday, March 17, 2023

Pharmabio Serv, Inc.

CIK: 1304161 Ticker: PBSV



Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2023


March 17, 2023


DORADO, PUERTO RICO / ACCESSWIRE / March 17, 2023 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2023 were approximately $4.2 million, a net decrease of approximately $0.8 million when compared to the same period last year. Net income for the quarter ended January 31, 2023 was approximately $0.4 million, an increase of approximately $0.1 million when compared to the same period last year.


"This quarter we were able to successfully maximize our resources in more profitable markets. This strategy yielded a positive effect on our overall gross profit percentage.  We plan to continue maximizing our resources to provide increased profitability,” stated Mr. Sanchez, Chief Executive Officer of the Company.


About Pharma-Bio Serv, Inc.


Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.


Forward-Looking Statements


This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2022, and in its other filings with the Securities and Exchange Commission, which filings are available on Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.


Company Contact:


Pedro J. Lasanta

Chief Financial Officer

787 278 2709

SOURCE: Pharma-Bio Serv, Inc.


View differences made from one to another to evaluate Pharmabio Serv, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Pharmabio Serv, Inc..


Assess how Pharmabio Serv, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Pharmabio Serv, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Pharmabio Serv, Inc. provided additional information to their SEC Filing as exhibits

Ticker: PBSV
CIK: 1304161
Form Type: 8-K Corporate News
Accession Number: 0001654954-23-003136
Submitted to the SEC: Fri Mar 17 2023 5:24:51 PM EST
Accepted by the SEC: Fri Mar 17 2023
Period: Friday, March 17, 2023
Industry: Management Consulting Services
  1. Earnings Release
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: